Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EPO Upholds Teva’s Copaxone 40mg Dosing-Regimen Patent

Executive Summary

Teva has won a victory in persuading the European Patent Office to uphold a Copaxone dosing patent that it had granted. But national courts may take a different view on validity.

You may also be interested in...

EPO Reversal Overturns Copaxone 40mg Patent

Mylan has celebrated a reversal from the European Patent Office that has seen a key patent protecting Teva’s higher-strength 40mg/ml thrice-weekly version of Copaxone deemed invalid and revoked across Europe. Meanwhile, Teva has commented on the possibility of an appeal.

No Irish bar for Teva on Mylan glatiramer

Teva has been refused by Ireland’s High Court an injunction to stop Mylan producing its US rival to Copaxone (glatiramer acetate) 40mg/ml at a local facility in Inverin, County Galway. The Israeli firm had claimed that Mylan’s production of the generic version of the multiple-sclerosis brand infringed the Irish counterpart of European patent EP2,949,335, titled ‘low frequency glatiramer acetate therapy’.

Mylan’s Brabio rivals Copaxone in the UK

Mylan has launched partner Synthon’s Brabio (glatiramer acetate) 40mg/ml in the UK, the first generic of Teva’s thrice-weekly Copaxone formulation to treat relapsing forms of multiple sclerosis available to the UK’s National Health Service (NHS).


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts